New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Feature|Articles|June 26, 2026
5 FDA decisions to watch for during 2H 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A preview of 5 pending FDA decisions for pediatric patients expected in the second half of 2026, spanning ADHD, psoriasis, a metabolic gene therapy, cardiomyopathy, and muscular dystrophy.
Advertisement
Advertisement
After a first half of 2026 that brought historic firsts for Menkes disease, arginase 1 deficiency, achondroplasia, plaque psoriasis, and the neurologic complications of Hunter syndrome, the FDA's pediatric pipeline shows no signs of slowing. The back half of the year carries a slate of priority review decisions spanning neurodevelopmental, cardiac, metabolic, and neuromuscular disease—several of which could establish the first pharmacologic options ever available to the children and adolescents they're intended to treat.
Related to this article
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.
Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
FDA approves Camzyos for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten becomes the first cardiac myosin inhibitor approved for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic oHCM.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Advertisement
Advertisement